financetom
Business
financetom
/
Business
/
Liberty Gold Gets Approval for Exploration Plan of Operations Amendment at Black Pine Oxide Gold Project in Idaho
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Liberty Gold Gets Approval for Exploration Plan of Operations Amendment at Black Pine Oxide Gold Project in Idaho
Jun 11, 2024 5:12 AM

07:14 AM EDT, 06/11/2024 (MT Newswires) -- Liberty Gold ( LGDTF ) on Tuesday said it received final approval from the U.S. Forest Service for an amendment to its exploration plan of operations at the Black Pine oxide gold project in Idaho, allowing exploration activities on USFS lands where the company holds mineral title but was not previously permitted to drill.

The permit amendment expands the current area for permitted exploration by 51% to 37.3 square kilometers. This will allow Liberty Gold ( LGDTF ) to explore seven new target areas where the prospective and permissive gold host-rock carbonate sequence is known to occur at shallow depth beneath sandstone cover rock.

The amended plan of operations also directs the Bureau of Land Management to start the process of issuing a Hardrock Prospector Permit over contiguous, highly prospective areas. The permit would open a further 7.1 square kilometers to approved exploration activities.

The company has staked 46 unpainted mining claims in the southwest of the project area, totaling 3.3 square kilometers. These claims are contiguous with the existing project area. The newly acquired ground expands the total project area to 69.3 square kilometers.

In addition, Liberty Gold ( LGDTF ) said it appointed Matthew Zietlow as its director of regulatory affairs and sustainability to advance mine permitting at Black Pine with federal and state agencies. The company aims to submit the mine plan of operations to regulatory agencies by the fourth quarter.

Liberty Gold's ( LGDTF ) share price lost 2.9% to $0.33 at close on Monday.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Medical aesthetic device maker Venus Concept's Q3 revenue misses
Medical aesthetic device maker Venus Concept's Q3 revenue misses
Nov 13, 2025
Overview * Venus Concept Q3 2025 revenue down 8% yr/yr, missing analyst expectations * Net loss widened to $22.5 mln in Q3, compared to $9.3 mln last year * Company completed debt-to-equity exchange, reducing debt by 24% Outlook * Company is not providing financial guidance for fiscal year 2025 * Company targets sequential growth in Q4 with Venus NOVA launch...
GoHealth Q3 revenue misses estimates on reduced Medicare Advantage volume
GoHealth Q3 revenue misses estimates on reduced Medicare Advantage volume
Nov 13, 2025
Overview * GoHealth Q3 2025 revenue declines 71% yr/yr, missing analyst expectations * Adjusted EBITDA for Q3 misses estimates, reflecting strategic pullback in Medicare Advantage * Company focuses on retention and quality amid changing Medicare market dynamics Outlook * Company secured superpriority term loan facility to enable strategic flexibility Result Drivers * MEDICARE ADVANTAGE PULLBACK - Co reduced Medicare Advantage...
Alliance Laundry Q3 Adjusted Earnings, Revenue Rise
Alliance Laundry Q3 Adjusted Earnings, Revenue Rise
Nov 13, 2025
07:11 AM EST, 11/13/2025 (MT Newswires) -- Alliance Laundry ( ALH ) reported Q3 adjusted earnings Thursday of $0.28 per share, up from $0.19 a year earlier. An analyst surveyed by FactSet expected $0.22. Net revenue for the quarter ended Sept. 30 was $437.6 million, up from $384.3 million. Analysts polled by FactSet expected $423.5 million. ...
Aura Biosciences Q3 net loss widens as R&D costs rise
Aura Biosciences Q3 net loss widens as R&D costs rise
Nov 13, 2025
Overview * Aura Biosciences ( AURA ) reports Q3 net loss of $26.1 mln, up from $21.0 mln last year * R&D expenses rise to $22.2 mln due to ongoing clinical trials Outlook * Aura expects Phase 3 CoMpass trial enrollment completion in 2026 * Topline data for CoMpass trial expected in Q4 2027 * Phase 1b/2 trial data for...
Copyright 2023-2025 - www.financetom.com All Rights Reserved